Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C.
Lee MY, et al.
J Immunother Cancer. 2021 Mar;9(3):e002128. doi: 10.1136/jitc-2020-002128.
J Immunother Cancer. 2021.
PMID: 33741731
Free PMC article.